Glucocorticoids and Rheumatoid Arthritis

被引：59
作者：
Ferreira, Joana Fonseca [1 ]
Mohamed, Alaa Abdelkhalik Ahmed [2 ]
Emery, Paul [3 ,4 ]
机构：
[1] Ctr Hosp & Univ Coimbra, Hosp Univ Coimbra, Rheumatol Unit, P-3000075 Coimbra, Portugal
[2] Assiut Univ Hosp, Rheumatol Phys Med & Rehabil Dept, Assiut 71515, Egypt
[3] Univ Leeds, Chapel Allerton Hosp, Leeds Teaching Hosp NHS Trust, Musculoskeletal Biomed Res Unit, Leeds LS7 4SA, W Yorkshire, England
[4] Univ Leeds, Chapel Allerton Hosp, Leeds Inst Rheumat & Musculoskeletal Med, Leeds LS7 4SA, W Yorkshire, England
来源：
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA | 2016年 / 42卷 / 01期
关键词：
Rheumatoid arthritis; Glucocorticoids; Prednisolone; Dose; Side effect; Drug-drug interactions; LOW-DOSE PREDNISOLONE; EULAR RECOMMENDATIONS; THERAPY; DISEASE; TRIAL; CHRONOTHERAPY; SAFETY;
D O I：
10.1016/j.rdc.2015.08.006
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Glucocorticoids (GCs) were discovered in the 1940s and were administered for the first time to patients with rheumatoid arthritis in 1948. However, side effects were subsequently reported. In the last 7 decades, the mechanisms of action for both therapeutic properties and side effects have been elucidated. Mechanisms for minimizing side effects were also developed. GCs are the most frequently used class of drugs in the treatment of rheumatoid arthritis because of their efficacy in relieving symptoms and their low cost. A review of clinical applications, side effects, and drug interactions is presented.
引用
收藏
页码：33 / +
页数：15
相关论文
共 42 条
  • [1] AVIOLI LV, 1993, BRIT J RHEUMATOL, V32, P27
  • [2] Glucocorticoid chronotherapy in rheumatoid arthritis
    Bijlsma, Johannes W. J.
    Jacobs, Johannes W. G.
    [J]. LANCET, 2008, 371 (9608) : 183 - 184
  • [3] Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
    Boers, M
    Verhoeven, AC
    Markusse, HM
    vandeLaar, MAFJ
    Westhovens, R
    vanDenderen, JC
    vanZeben, D
    Dijkmans, BAC
    Peeters, AJ
    Jacobs, P
    vandenBrink, HR
    Schouten, HJA
    vanderHeijde, DMFM
    Boonen, A
    vanderLinden, S
    [J]. LANCET, 1997, 350 (9074) : 309 - 318
  • [4] Glucocorticoids in the treatment of rheumatic diseases - An update on the mechanisms of action
    Buttgereit, F
    Straub, RH
    Wehling, M
    Burmester, GR
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (11): : 3408 - 3417
  • [5] Buttgereit F, 2003, CLIN EXP RHEUMATOL, V21, P145
  • [6] Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial
    Buttgereit, Frank
    Doering, Gisela
    Schaeffler, Achim
    Witte, Stephan
    Sierakowski, Stanislaw
    Gromnica-Ihle, Erika
    Jeka, Slawomir
    Krueger, Klaus
    Szechinski, Jacek
    Alten, Rieke
    [J]. LANCET, 2008, 371 (9608) : 205 - 214
  • [7] Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)
    Buttgereit, Frank
    Mehta, Daksha
    Kirwan, John
    Szechinski, Jacek
    Boers, Maarten
    Alten, Rieke E.
    Supronik, Jerzy
    Szombati, Istvan
    Romer, Ulrike
    Witte, Stephan
    Saag, Kenneth G.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (02) : 204 - 210
  • [8] Exogenous and Endogenous Glucocorticoids in Rheumatic Diseases
    Buttgereit, Frank
    Burmester, Gerd-Ruediger
    Straub, Rainer H.
    Seibel, Markus J.
    Zhou, Hong
    [J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (01): : 1 - 9
  • [9] A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs
    Choy, EH
    Kingsley, GH
    Khoshaba, B
    Pipitone, N
    Scott, DL
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (09) : 1288 - 1293
  • [10] Criswell LA., 2000, COCHRANE DB SYST REV, V1998, pCD001158, DOI 10.1002/14651858.CD001158
12345